[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354021-105":59,"doc-detail-354021-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","preclinical-evaluation-of-aht-102-a-cldn182-cd3-bispecific-antibody-pharmacokinetics-anti-tumor-efficacy-tissue-distribution-and-safety-profile","Preclinical Evaluation of AHT-102, a CLDN18.2 × CD3 Bispecific Antibody - Pharmacokinetics, Anti-Tumor Efficacy, Tissue Distribution, and Safety Profile","","Claudin18.2 (CLDN18.2) is a therapeutic target frequently overexpressed across tumor tissues, while CD3-engaging bispecific antibodies may be limited by inadequate solid-tumor efficacy and clinically relevant safety hazards such as cytokine release syndrome. This study comprehensively characterizes AHT-102, an Fc-free CLDN18.2 × CD3 bispecific with a low-affinity CD3 arm. The work evaluates anti-tumor activity, pharmacokinetics, quantitative tissue distribution, and long-term safety to support clinical development potential.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/preclinical-evaluation-of-aht-102-a-cldn182-cd3-bispecific-antibody-pharmacokinetics-anti-tumor-efficacy-tissue-distribution-and-safety-profile/354021/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/preclinical-evaluation-of-aht-102-a-cldn182-cd3-bispecific-antibody-pharmacokinetics-anti-tumor-efficacy-tissue-distribution-and-safety-profile/354021.png","ImageObject",300,407,{"name":92,"@type":93},"Jordan Avery","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is AHT-102 and what problem does it aim to address?","Question",{"text":112,"@type":113},"AHT-102 is an Fc-free CLDN18.2 × CD3 bispecific antibody designed to improve solid-tumor anti-tumor efficacy while mitigating safety risks such as cytokine release syndrome.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was anti-tumor efficacy evaluated in this preclinical study?",{"text":117,"@type":113},"Anti-tumor efficacy was assessed in CLDN18.2-positive gastric cancer mouse models (NUGC4-CLDN18.2), using different AHT-102 dose levels to demonstrate dose-dependent tumor suppression.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the study show about pharmacokinetics, tissue distribution, and safety?",{"text":121,"@type":113},"In human CD3EDG transgenic mice, AHT-102 displayed linear pharmacokinetic characteristics with refined terminal half-lives across tested doses. Tissue distribution showed high tumor targeting specificity and reduced lymph node accumulation, and the maximum tolerated dose reached 13.65 mg/kg with dose-dependent gastric damage that was reversible after discontinuation.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354021,1790635912,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},1099523882367,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Drugs in R&D (2026) 26:39–50  \n[https://doi.org/10.1007/s40268-026-00535-y](https://doi.org/10.1007/s40268-026-00535-y)  \nPreclinical Evaluation of AHT‑102, a CLDN18.2 × CD3 Bispecific Antibody: Pharmacokinetics, Anti‑Tumor Efficacy, Tissue Distribution, and Safety Profile  \nHuilun Chu1 · Guili Xu2 · Yunlong Liu3 · Niliang Qian2 · Yanchuan Li4 · Yujie Liu2 · Xiujie Pan2 · Xin Gao2 · Lun Ou3 · Junping Lv1 · Haifeng Song5  \nReceived: 3 April 2025 / Accepted: 19 January 2026 / Published online: 26 February 2026 © The Author(s) 2026  \nAbstract  \nBackground and Objectives Claudin18.2 (CLDN18.2) is a promising therapeutic target overexpressed in various tumor tissues. While CD3-engaging bispecific antibodies show great potential, their clinical application is often limited by poor efficacy in solid tumors and significant safety risks, such as cytokine release syndrome (CRS) . The objective of this study was to comprehensively evaluate the preclinical anti-tumor efficacy, pharmacokinetics, tissue distribution, and safety profile of AHT-102, a novel Fc-free CLDN18.2 × CD3 bispecific antibody with a low-affinity CD3 arm, to determine its potential for clinical development.  \nMethods This study evaluated the anti-tumor efficacy of AHT-102 in CLDN18.2-positive gastric cancer mouse models (NUGC4-CLDN18.2) . We further assessed its pharmacokinetic characteristics, quantitative tissue distribution using 125I-labeling, and long-term toxicity in human CD3EDG transgenic mice.  \nResults AHT-102 (0.1, 0.3, and 1 mg/kg) demonstrated significant dose-dependent anti-tumor effects, with tumor weight inhibition reaching 51% at the 1-mg/kg dose. Pharmacokinetic analysis in CD3EDG mice revealed linear characteristics with refined terminal half-lives of 0.762 h, 3.05 h, and 4.25 h for doses of 0.1, 0.5, and 2.5 mg/kg, respectively. Tissue distribution studies confirmed superior targeting specificity; the tumor-to-muscle ratio exceeded 15, and the molecule successfully bypassed the ‘T-cell sink’ by showing lower accumulation in the lymph nodes compared with the tumor. In vitro, AHT-102 did not induce target-independent cytokine release from peripheral blood mononuclear cells (PBMCs) . The maximum tolerated dose (MTD) in human CD3EDG mice reached 13.65 mg/kg, a 136.5-fold margin over the projected clinical starting dose. Observed gastric tissue damage was dose-dependent and reversible upon drug discontinuation.  \nConclusions AHT-102, a novel Fab-like bispecific antibody, achieves an optimized therapeutic balance through its lowaffinity CD3 arm and Fc-free format. It demonstrates significant anti-tumor efficacy and exceptional targeting specificity while avoiding systemic immunotoxicity typically associated with CD3-targeting agents. These findings provide a robust scientific rationale for the clinical translation of AHT-102 in patients with CLDN18.2-positive cancers.  \n1 Introduction  \nIn recent decades, significant progress has been made in cancer immunotherapy. However, due to the limited availability of specific antigen targets, high tumor heterogeneity, and the challenging tumor microenvironment (TME), immunotherapy for solid tumors remains a formidable challenge. There is an urgent need for novel therapies with tumor-targeted immune activation properties to address these characteristics.  \nExtended author information available on the last page of the article  \nClaudins (CLDNs) constitute a protein family essential for maintaining tight junctions that regulate molecular exchange between cells. Within this family, CLDN18 exists in two isoforms, CLDN18.1 and CLDN18.2 . CLDN18.2, a highly selective biomarker, exhibits limited expression in normal tissues but frequently undergoes abnormal expression in the development of various primary malignancies, such as gastric cancer (GC), pancreatic cancer, esophageal cancer, breast cancer, colorectal cancer, liver cancer, head and neck tumors, bronchial carcinoma, and non-small cell lung cancer [1] . In 2023, the ","cbCaipPhHZ0zbQSQ","https://ap.wps.com/l/cbCaipPhHZ0zbQSQ","pdf",2663957,12,"English","# Abstract\n## Background and Objectives\n## Methods\n## Results\n## Conclusions\n# Key Points\n# Introduction","[{\"question\":\"What is AHT-102 and what problem does it aim to address?\",\"answer\":\"AHT-102 is an Fc-free CLDN18.2 × CD3 bispecific antibody designed to improve solid-tumor anti-tumor efficacy while mitigating safety risks such as cytokine release syndrome.\"},{\"question\":\"How was anti-tumor efficacy evaluated in this preclinical study?\",\"answer\":\"Anti-tumor efficacy was assessed in CLDN18.2-positive gastric cancer mouse models (NUGC4-CLDN18.2), using different AHT-102 dose levels to demonstrate dose-dependent tumor suppression.\"},{\"question\":\"What did the study show about pharmacokinetics, tissue distribution, and safety?\",\"answer\":\"In human CD3EDG transgenic mice, AHT-102 displayed linear pharmacokinetic characteristics with refined terminal half-lives across tested doses. Tissue distribution showed high tumor targeting specificity and reduced lymph node accumulation, and the maximum tolerated dose reached 13.65 mg/kg with dose-dependent gastric damage that was reversible after discontinuation.\"}]","Preclinical Evaluation of AHT-102, a CLDN18.2 × CD3 Bispecific Antibody - Pharmacokinetics, Anti-Tumor Efficacy, Tissue Distribution, and Safety Profile | PDF",1790108491,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/566783114e69f05aa5ef54ac7ae9b0d3.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7ee5d18ba1dd9eeea23f6101a4c8dfd8.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/acf5d7cc5900111ec30f48796ab7b441.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ebb389a0f195a1d3f245c334b077f154.webp",980,1301]